Please assess the completion status of the following clinical trial:

Trial Title: Anakinra for COVID-19 Respiratory Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Male or female≥ 18 years of age~* Written informed consent of the patient or a proxy~* Ability for participant to comply with the requirements of the study~* Hospitalized patient with COVID-19 defined as~  * Positive SARS-CoV2 RT-PCR~ * Or typical COVID-19 Radiographic infiltrates on the CT scan (peripheral ground glass without lung cavitation, lymphadenopathy, or pulmonary nodules) other non COVID-19 diagnosis ruled out.~* Patient with respiratory symptoms and requirement of oxygen therapy as defined:~  * Oxygen therapy \>= 4L/min to maintain Sp02\>92% and respiratory rate \>=24/min.~ * Or patients under oxygen \>= 1L/min and presenting worsening of oxygen requirement defined by an increase of oxygen therapy \>= 2L/min to maintain Sp02\>92%.~* Inflammatory component C-Reactive Protein ≥ 50mg/L.~* Patients within the first 20 days from the onset of the first COVID-19 symptoms~* Probabilistic antibiotics therapy according to local practice~Non-inclusion criteria:~* Respiratory failure related to other cause than COVID-19~* Patients requiring mechanical ventilation at inclusion or requiring oxygen therapy equal or more than 11 liters per min to maintain Sp02\>92%~* Infectious diseases such as severe bacterial infections, aspergillosis, HIV, active HCV, active HBV, active tuberculosis~* Contra indication to anti-IL1 receptor~  * Known hypersensitivity to Anakinra~ * Absolute neutrophil count (ANC)\< 1500/mm3~ * Liver cirrhosis Child-Pugh Score C~ * Live or attenuated vaccine in the past 8 weeks~ * Pregnant or breast-feeding women~* Patients with either legally protected status or who have been deprived of their freedom~* Patient included in other interventional therapeutic research (e.g. = concurrent participation in French CoVID-19 is accepted)~* Patients who have received previous treatment by anti-IL6R, anti-IL-6, anti-IL1R, anti-IL1 or anti-TNFα within 21 days preceding inclusion~* Absence of Health Insurance~* Existence of any life-threatening co-morbidity or any other medical condition which,in the opinion of the investigator, makes the patient unsuitable for inclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Optimized Standard of Care (oSOC) (Type: ACTIVE_COMPARATOR): The control group will receive optimized standard of care alone, including all treatments authorized for COVID-19 by the French Health Ministry and/or the center COVID-19 therapeutic committees at inclusion and during the follow-up.
- Anakinra plus Optimized Standard of Care (oSOC) (Type: EXPERIMENTAL): The experimental group will receive Anakinra plus optimized Standard of Care. The patients will receive Intravenous injection (IV) of Anakinra 400mg/day (100mg IV every 6 hours) at Day 1, 2 and 3. From Day 4 to Day 10, the patient will receive IV injection of Anakinra 200mg/day (100mg every 12 hours). The total duration of Anakinra is 10 Days

Based on this trial design, predict the completion outcome and termination type (if applicable).